SCYNEXIS (SCYX) vs Veru (VERU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SCYNEXIS (SCYX) has outperformed Veru (VERU) over the past year, losing 32.1% versus a loss of 45.1%. Over five years, SCYX leads with a -90.5% price change compared with -97.2% for VERU. Veru is the larger company by market cap ($42.0 million vs $41.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCYX | VERU |
|---|---|---|
| Share price | $4.13 | $2.46 |
| Market cap | $41.04M | $41.98M |
| 1-day change | -2.25% | +1.75% |
| YTD return | -16.53% | +13.08% |
| 1-year return | -32.11% | -45.12% |
| 5-year return | -90.53% | -97.18% |
| EPS (TTM) | $-0.89 | $-0.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.12 | $7.33 |
| 52-week low | $3.53 | $2.05 |
| Distance from 52-week high | -54.77% | -66.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +780.73% | +942.52% |
| Average volume | 279.10K | 242.06K |
| Shares outstanding | 9.95M | 17.05M |
| Employees | 18 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed VERU by 13.0 percentage points over the past year.
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
About Veru
VERU stock →Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
SCYX vs VERU FAQ
Which is bigger, SCYNEXIS or Veru?
Veru (VERU) is larger, with a market capitalization of $41.98M compared with $41.04M for SCYNEXIS (SCYX).
Which stock has performed better over the past year, SCYX or VERU?
SCYX returned -32.11% over the past 12 months, compared with -45.12% for VERU (price return, excluding dividends). Past performance does not predict future results.
Are SCYNEXIS and Veru in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.